University Medical Center Groningen

Atrasentan significantly reduced proteinuria in IgA nephropathy patients, showing a 36.1 percentage point greater reduction in urinary protein-to-creatinine ratio (UPCR) compared to placebo in the ALIGN study. The drug demonstrated a 38.1% reduction in UPCR over 36 weeks, with significant reduction by week 6. The study's final results will confirm if this reduction translates to preserved kidney function.

Semaglutide, known for weight loss, improves kidney health in CKD patients, reducing protein in urine by 52%, kidney inflammation by 30%, and heart failure risk by 33%, with average weight loss of 10%. Direct benefits include reduced kidney inflammation and fat deposits, while indirect benefits stem from weight and blood pressure reduction. Future studies aim to explore semaglutide's potential to reduce dialysis and transplant needs.

Semaglutide reduced urine albumin-to-creatinine ratio by over 50% in adults with CKD, overweight or obesity, and no diabetes, also significantly decreasing weight and blood pressure.

Semaglutide (Ozempic) showed a 52.1% reduction in urine albumin-to-creatinine ratio (UACR) in a 6-month trial for nondiabetic CKD patients with obesity, suggesting potential kidney protection and warranting further clinical trials.

ASN Kidney Week 2024 will present results from high-impact phase 3 trials on finerenone, personalized AKI recommendations, semaglutide, tacrolimus vs. mycophenolate mofetil, empagliflozin, and HSK21542 for CKD-associated pruritus, highlighting kidney protective effects, efficacy, and safety of these treatments.

The gut microbiome's balance affects autoimmune diseases, with dysbiosis leading to altered immune responses. Beneficial gut bacteria produce short-chain fatty acids that aid immune cell development, while microbial metabolites and peptides can regulate immune cell activity. Imbalances in gut microbiota, such as changes in Bacteroidetes/Firmicutes ratio, contribute to diseases like rheumatoid arthritis and multiple sclerosis. Precision medicine aims to manipulate the gut microbiome to improve autoimmune therapy, though human studies are needed to better understand these complex interactions.

Ipsen's Kayfanda® (odevixibat) approved in the European Union for treating cholestatic pruritus in Alagille Syndrome, a rare liver disease, based on ASSERT Phase III trial data showing significant itch reduction and improved sleep.

Kayfanda® (odevixibat) approved for treating cholestatic pruritus in children with Alagille Syndrome, based on ASSERT Phase III trial data showing significant itch reduction and improved sleep. Kayfanda is a non-systemic IBAT inhibitor, expanding Ipsen's rare cholestatic liver disease portfolio.

Ipsen's Kayfanda® (odevixibat) approved by the European Commission for treating cholestatic pruritus in Alagille Syndrome patients aged 6 months or older, based on ASSERT Phase III trial data showing significant itch reduction and improved sleep parameters.

Ipsen’s Kayfanda® (odevixibat) approved in the E.U. for treating cholestatic pruritus in Alagille Syndrome, based on ASSERT Phase III trial data showing significant itch reduction and improved sleep parameters.